Wall Street Fundamentals Releases New In-Depth Stock Reports on AMBI, BIND, CGIX and PETXadmin
The Biotech industry has continued to outpace the broader markets in 2013. The iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and the SPDR S&P Biotech ETF (NYSEARCA: XBI) year-to-date have posted gains of approximately 60.0 percent and 43.0 percent, respectively, compared to the S&P 500 Index’s gain of 26.0 percent. The success the Biotech Industry has experienced in recent years has caused a surge in IPO’s this year. According to data from Credit Suisse, 38 have gone public through mid-November, the most since 2000.
Ambit Biosciences Corp. (NASDAQ: AMBI) shares traded in the range of $8.01 to $8.48 Tuesday before settling to close at $8.16, a decrease of 1.81 percent. The stock appears to be facing some resistance at the $11.21, $11.80 and $13.00 levels. Shares of Ambit Biosciences have gained approximately 10.0 percent since its IPO.
More information on Ambit Biosciences and access to the free equity report can be found at:
BIND Therapeutics Inc. (NASDAQ: BIND) shares traded in the range of $12.00 to $12.97 Tuesday before settling to close at $12.88, an increase of 4.38 percent. The stock appears to be facing some resistance at the $15.78 with some support at $11.09. Shares of BIND Therapeutics have fallen approximately 8.0 percent since its IPO.
More information on BIND Therapeutics and access to the free equity report can be found at:
Cancer Genetics Inc. (NASDAQ: CGIX) shares traded in the range of $11.91 to $12.30 Tuesday before settling to close at $12.11, an increase of 0.25 percent. The stock appears to be facing some resistance at the $13.35 and $15.17 levels with some support at $11.66. Shares of Cancer Genetics have gained approximately 33.0 percent since it IPO.
More information on Cancer Genetics and access to the free equity report can be found at:
Aratana Therapeutics Inc. (NASDAQ: PETX) shares traded in the range of $17.75 to $18.67 Tuesday before settling to close at $18.20, a decrease of 2.67 percent. The stock appears to be facing some resistance at the $19.39, $21.61 and $22.94 levels. Shares of Aratana Therapeutics have gained approximately 120.0 percent since its IPO.
More information on Aratana Therapeutics and access to the free equity report can be found at:
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Posted: December 11th, 2013 under ACCESSWIRE.